GalvãoTFG. Is There Any Cardiovascular Concern Regarding the Use of Aromatase Inhibitors in Breast Cancer?. Arq. Bras. Cardiol. 2019;112(5):489-90.
Galvão,Tatiana F. G.. Is There Any Cardiovascular Concern Regarding the Use of Aromatase Inhibitors in Breast Cancer?. Arq. Bras. Cardiol., v. 112, n. 5, p. 489-490, May. 2019.
Galvão,T.F.G. (2019). Is There Any Cardiovascular Concern Regarding the Use of Aromatase Inhibitors in Breast Cancer?. Arq. Bras. Cardiol.,112(5), 489-490.
Galvão,Tatiana F. G.. Is There Any Cardiovascular Concern Regarding the Use of Aromatase Inhibitors in Breast Cancer?. Arq. Bras. Cardiol. [online]. 2019, vol. 112, n. 5, [cited 2025-09-07], pp.489-490. Available from: <https://abccardiol.org/en/article/is-there-any-cardiovascular-concern-regarding-the-use-of-aromatase-inhibitors-in-breast-cancer/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.
